TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8730247
Drug: Anti-H. pylori
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-H. pylori treatment with different drugs
Study: 27632268
Drug: Laser-microtextured implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laser-microtextured implants
Study: 23101262
Drug: Liniment cycloferon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liniment cycloferon included in combined therapy
Study: 12204802
Drug: Atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10 mg/day (A10)
Study: 12204802
Drug: Simvastatin 20
Normalized name: simvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin 20 mg/day (S20)
Study: 8452322
Drug: Enalapril, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril, 10 mg per day
Study: 3539796
Drug: Felodipine (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (acute oral administration)
Study: 3539796
Drug: Felodipine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (1 week treatment)
Study: 3539796
Drug: Felodipine (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (6 weeks treatment)
Study: 3539796
Drug: Felodipine (withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine (withdrawal of treatment)
Study: 23294350
Drug: Topical sialogogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical sialogogue spray containing 1% malic acid
Study: 4560057
Drug: L-5-hydroxytryptophan with
Normalized name: L-5-HTP
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-5-hydroxytryptophan with a peripheral decarboxylase inhibitor
Study: 31204115
Drug: Drug-coated balloon
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-coated balloon (paclitaxel and iopromide)
Study: 28860894
Drug: 28 mL
Normalized name: ethanol 0.28 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 28 mL of 370 mgI/mL iodinated contrast media at a flow rate of 3.5 mL/s
Study: 28860894
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL of 370 mgI/mL iodinated contrast media at a flow rate of 5 mL/s
Study: 16563715
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg of salbutamol
Study: 16563715
Drug: Inhaled budesonide
Normalized name: budesonide Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled budesonide (after 6 and 12 weeks of therapy)
Study: 16563715
Drug: Clinical severity
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical severity indicators and blood markers (including daily PEF variation, rescue bronchodilator use, severity of asthmatic symptoms, blood eosinophil count, serum eosinophilic cationic protein, and eosinophilic protein X concentrations)
Study: 9519501
Drug: Nifedipine GITS
Normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine GITS 60 mg o.d.
Study: 9519501
Drug: Atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 100 mg o.d.
Study: 3481149
Drug: Grenz ray
Normalized name: Ray Dol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grenz ray therapy
Study: 29692206
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mg/day)
Study: 22821660
Drug: Fuzheng Huayu
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fuzheng Huayu Tablet (FZHYT)
Study: 20887348
Drug: Long-acting ß2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting ß2-agonist and inhaled glucocorticoid (fluticasone propionate) for 3 months (group 2)
Study: 20887348
Drug: Long-acting ß2-agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting ß2-agonist (salmeterol) for 3 months (group 1)
Study: 18424594
Drug: L-alpha-glycerophosphocholine (L-alpha)
Normalized name: L-alpha-Glycerophosphocholine
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alpha-glycerophosphocholine (L-alpha) added to vegetarian lasagna
Study: 18424594
Drug: Ascorbic acid
Normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbic acid (100 mg) added to vegetarian lasagna
Study: 16382035
Drug: Albendazole at
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole at 15 mg/kg/day plus dexamethasone for 8 days
Study: 16382035
Drug: Albendazole at
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole at 30 mg/kg/day plus dexamethasone for 8 days
Study: 16382035
Drug: Albendazole (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (any dose)
Study: 10391534
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with 0.625 mg/day of conjugated equine estrogen (CEE) or 50 microg/day of 17‐beta‐Estradiol in transdermal therapeutic systems (TTS), plus 5 mg/day of medroxyprogesterone acetate for those with natural menopause for the last 12 days of therapy.
Study: 8874325
Drug: High-dose interferon
Normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose interferon alfa-2b (IFN alpha 2b) treatment
Study: 6213195
Drug: Piperacillin (2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piperacillin (2.0 g) with 1.0 g probenecid
Study: 6213195
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G (4.8 X 10(6) U) with 1.0 g probenecid
Study: 25112083
Drug: Electroacupuncture at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture at eight-neck-occiput points (Neck 1-4 points, Occiput 1-4 points), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Study: 25112083
Drug: Routine acupoints
Normalized name: Peace Out Acne Hero Routine KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine acupoints (Lianquan (CV 23), Futu (LI 18), Tongli (HT 5), Hegu (LI 4), and others), treatment once a day for 4 weeks, 5 treatments a week, using dense-dispersion wave for 30 minutes.
Study: 12777270
Drug: High-dose branched-chain
Normalized name: Machilus thunbergii branch extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose branched-chain amino acids (222 mg/kg of body weight t.i.d.)
Study: 9176846
Drug: Unremitting proteinuria
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unremitting proteinuria during the initial 8 weeks of treatment
Study: 3898911
Drug: 5% lidocaine-prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% lidocaine-prilocaine cream (EMLA) applied for 20 min or longer
Study: 22042116
Drug: Intravenous tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous tramadol and intrapleural saline solution (Group A)
Study: 22042116
Drug: Intravenous dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dipyrone and intrapleural 0.33% ropivacaine (Group B)
Study: 22042116
Drug: Intravenous dipyrone
Normalized name: dipyrone
DrugBank: Metamizole (DB04817)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dipyrone and intrapleural 0.5% ropivacaine (Group C)
Study: 16686840
Drug: PCT (photochemical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT (photochemical treatment with amotosalen HCl and ultraviolet A light)
Study: 15043516
Drug: Rofecoxib (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib (12.5 mg/day)
Study: 7721498
Drug: Bisoprolol 10
Normalized name: bisoprolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol 10 mg once daily
Study: 11092108
Drug: Bisoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol plus nifedipine 20 mg twice daily
Study: 11092108
Drug: Bisoprolol plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol plus amlodipine 5 mg once daily
Study: 8454139
Drug: 50% glucose/water
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50% glucose/water solution
Study: 3749811
Drug: High-dose liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose liquid antacid
Study: 29356271
Drug: Regenerative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regenerative serum (Matricium®) applied twice daily for 2 months after fractional laser procedure
Study: 29356271
Drug: Placebo applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo applied twice daily for 2 months after fractional laser procedure
Study: 26807488
Drug: First-line platinum/taxane
Approvals — FDA: no, EMA: no, PMDA: no
Description: First-line platinum/taxane combination chemotherapy
Study: 21083385
Drug: VX-770 150
Normalized name: VX-121
DrugBank: Vanzacaftor (DB18373)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VX-770 150 mg
Study: 16404415
Drug: Plant sterol
Normalized name: plant sterol complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plant sterol group (2 g/day)
Study: 1914375
Drug: Grapefruit juice
Normalized name: grapefruit juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grapefruit juice (150 ml)
Study: 4076364
Drug: 4 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 puffs of 50 micrograms BDP twice daily (AM/PM)
Study: 4076364
Drug: 8 puffs
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 puffs of 50 micrograms BDP once daily (AM)
Study: 29915962
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin nasal spray
Study: 26465232
Drug: House dust
Normalized name: House dust
DrugBank: House dust (DB10345)
Approvals — FDA: no, EMA: no, PMDA: no
Description: House dust mite sublingual immunotherapy (HDM AIT)
Study: 11209008
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg cerivastatin
Study: 15977099
Drug: 0.8 mg
Normalized name: biotin 0.8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg cerivastatin
Study: 14654482
Drug: Catheter-directed thrombolytic
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheter-directed thrombolytic therapy with various plasminogen activators
Study: 10354297
Drug: Intravenous ascorbic
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ascorbic acid (IVAA) 300 mg three times per week for eight weeks
Study: 10354297
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IVAA treatment)
Study: 7589016
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Lisinopril
Study: 7589016
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Bisoprolol
Study: 9309369
Drug: Ceftibuten 200
Normalized name: ceftibuten 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftibuten 200 mg b.i.d.
Study: 2013204
Drug: Ceftibuten 300
Normalized name: Ceftibuten
DrugBank: Ceftibuten (DB01415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftibuten 300 mg b.i.d.
Study: 2013204
Drug: Cefaclor 500
Normalized name: cefaclor 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 500 mg t.i.d.
Study: 6802657
Drug: Lecithin (32
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin (32 g daily, 25% phosphatidylcholine)
Study: 25055558
Drug: Erythropoietin (EPO)
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (EPO) treatment (50 IU monthly for 6 months)
Study: 25055558
Drug: Traditional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional treatment of CHF
Study: 22265113
Drug: Mandatory-random student
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory-random student drug testing (MRSDT) implemented immediately in treatment schools
Study: 22265113
Drug: Mandatory-random student
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandatory-random student drug testing (MRSDT)
Study: 17963300
Drug: Peg-interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peg-interferon alpha-2b treatment
Study: 9559842
Drug: Transrectal microwave
Normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transrectal microwave hyperthermia (TMH) therapy
Study: 7650439
Drug: Buflomedil 600
Normalized name: buflomedil 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buflomedil 600 mg/day for 14 days
Study: 7650439
Drug: Placebo 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 600 mg/day for 14 days
Study: 2664884
Drug: Perphenazine 16
Normalized name: perphenazine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perphenazine 16 mg
Study: 2664884
Drug: Perphenazine 32
Normalized name: Perphenazine
DrugBank: Perphenazine (DB00850)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Perphenazine 32 mg
Study: 322570
Drug: Pseudoephedrine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pseudoephedrine (60 mg tablet)
Study: 322570
Drug: Ephedrine nasal
Normalized name: ePHEDrine nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ephedrine nasal spray (positive control)
Study: 28460195
Drug: Probiotic capsules
Normalized name: Quad-Probiotic Capsules
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsules (PRO)
Study: 25458558
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate (0.9 mg/m²) in combination with pemetrexed (500 mg/m²) on day 1 of a 21-day cycle (E+P)
Study: 25458558
Drug: Eribulin mesylate
Normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Eribulin mesylate in combination with pemetrexed (E+P)
Study: 21865334
Drug: 0.45 g
Normalized name: SODIUM CHLORIDE 0.45 g in 15 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.45 g n-3 LC-PUFAs/d
Study: 21865334
Drug: 0.9 g
Normalized name: Mannose 0.9 GM/1 DOSE Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9 g n-3 LC-PUFAs/d
Study: 21865334
Drug: 1.8 g
Normalized name: Calciquid, 1.8 g/5 mL oral syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.8 g n-3 LC-PUFAs/d
Study: 17283559
Drug: ipratropium/xylometazoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipratropium/xylometazoline 1.0 mg/mL
Study: 17283559
Drug: ipratropium/xylometazoline 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipratropium/xylometazoline 0.5 mg/mL
Study: 17283559
Drug: xylometazoline 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: xylometazoline 1.0 mg/mL
Study: 17283559
Drug: ipratropium 0.6
Normalized name: ipratropium 0.6 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipratropium 0.6 mg/mL
Study: 15522021
Drug: Cultured autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cultured autologous melanocytes plus PUVA therapy (CMP)
Study: 15522021
Drug: Suction blister
Normalized name: Blister Armour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suction blister transplantation plus PUVA therapy (SBP)
Study: 15522021
Drug: Cryotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy plus PUVA therapy (CP)
Study: 15522021
Drug: Only PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only PUVA therapy (OP)
Study: 9492090
Drug: Piracetam (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (40 mg/kg/day in 2 divided doses for 2 months)
Study: 27464024
Drug: Oral compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral compound glycyrrhizin (OCG)
Study: 27464024
Drug: UVB applications
Normalized name: zinc oxide
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: UVB applications twice weekly
Study: 22463890
Drug: Oxandrolone, 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxandrolone, 0.1 mg/kg twice daily for 12 months
Study: 16909273
Drug: Ibuprofen arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen arginate (600 mg)
Study: 16909273
Drug: Dexibuprofen (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexibuprofen (400 mg)
Study: 11508399
Drug: Myrrh (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myrrh (12 mg/kg per day for 6 consecutive days)
Study: 3689630
Drug: Inhaled fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled fenoterol hydrobromide (360 micrograms)
Study: 8042809
Drug: Inhaled ipratropium
Normalized name: ipratropium Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ipratropium bromide (72 micrograms)
Study: 3689630
Drug: Oral salbutamol
Normalized name: salbutamol
DrugBank: Albuterol (DB01001)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral salbutamol sulphate (4 mg)
Study: 3689630
Drug: Oral pirenzepine
Normalized name: pirenzepine
DrugBank: Pirenzepine (DB00670)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral pirenzepine hydrochloride (50 mg)
Study: 27160142
Drug: Vaginal Alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Alpha Lipoic Acid (10 mg)
Study: 27160142
Drug: Vaginal Progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal Progesterone (400 mg)
Study: 23551886
Drug: Testosterone Undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone Undecanoate (TU) 1,000 mg
Study: 14627851
Drug: Correlation analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation analysis between L/L ratio and GUI
Study: 9384462
Drug: 6-mercaptopurine (6MP)
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6MP) at 75 mg m(‐2)
Study: 29472198
Drug: Kangaroo mother
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kangaroo mother care (KMC) initiated at birth or 1 hour after birth in combination with standard thermoregulation care
Study: 22070666
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy followed by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy
Study: 22070666
Drug: Systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic chemotherapy only (Control)
Study: 8325279
Drug: Clobazam 20
Normalized name: cloBAZam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clobazam 20 mg/day for a minimum of 7 days before a second iomazenil study (Group 1, n = 7)
Study: 18060212
Drug: Diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac sodium 150 mg/day
Study: 12952269
Drug: Bosentan (add-on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bosentan (add-on therapy)
Study: 8935224
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole q.d. for 28 days plus 750 mg amoxicillin b.i.d. for the first 10 days (omep-20-amox group, N = 22)
Study: 8935224
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole b.i.d. for 28 days plus 750 mg amoxicillin b.i.d. for the first 10 days (omep-40-amox group, N = 22)
Study: 8935224
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg bismuth subsalicylate q.i.d. for 28 days, and 750 mg amoxicillin b.i.d., 500mg metronidazole t.i.d. for the first 7 days (triple therapy group, N = 25)
Study: 8935224
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole q.d. for 28 days (omep-20 group, N = 22)
Study: 8935224
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg ranitidine b.i.d. or 400 mg cimetidine b.i.d. for 28 days (H2-antagonist group, N = 21)
Study: 8935224
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy group (N = 25)
Study: 8935224
Drug: Omep-20-amox, omep-40-amox,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omep-20-amox, omep-40-amox, triple therapy, omep-20 groups
Study: 8935224
Drug: H2 antagonist
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: H2 antagonist group
Study: 1526418
Drug: 5-aminosalicylic acid
Normalized name: 5-aminosalicylic acid
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminosalicylic acid enema (1 g daily for 2 weeks)
Study: 1526418
Drug: Hydrocortisone acetate
Normalized name: Hydrocortisone Acetate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone acetate foam (90 mg daily for 2 weeks)
Study: 28724423
Drug: Telephone-administered short-term
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Telephone-administered short-term cognitive-behavioural therapy (T-CBT)
Study: 26151135
Drug: Yokukansan (YKS)
Normalized name: YK-4-279
DrugBank: YK-4-279 (DB17428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yokukansan (YKS) 2.5 g/day
Study: 26151135
Drug: Yokukansan (YKS)
Normalized name: YK-4-279
DrugBank: YK-4-279 (DB17428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yokukansan (YKS) 5.0 g/day
Study: 24923986
Drug: Yokukansan (YKS)
Normalized name: YK-4-279
DrugBank: YK-4-279 (DB17428)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yokukansan (YKS) 7.5 g/day
Study: 11100345
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of absolute alcohol (n = 44)
Study: 11100345
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of absolute ethanol + octreotide (n = 42)
Study: 11100345
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of absolute ethanol + omeprazole (n = 40)
Study: 11941338
Drug: Nonextraction orthodontic
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonextraction orthodontic treatment
Study: 11941338
Drug: Extraction orthodontic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extraction orthodontic treatment